Last updated: February 23, 2026
What is NDC 00904-7419?
NDC 00904-7419 refers to a specific prescription drug listed in the National Drug Code directory. Based on available public data, this code corresponds to Estradiol Transdermal System, 0.1 mg/day, old formulation. It is a hormone replacement therapy (HRT) indicated for estrogen deficiency and menopausal symptom management.
Market Landscape Overview
Market Size and Demand Drivers
The estrogen replacement market primarily addresses:
- Menopause symptom relief
- Hypoestrogenism conditions
- Hormone therapy for transgender women
Estimates suggest the global menopause market reaches $1.6 billion in 2022, with a compound annual growth rate (CAGR) of approximately 4% expected through 2028. The United States accounts for roughly 70% of this market.
Competitive Environment
NDC 00904-7419 competes with several other transdermal estrogen formulations:
| Product Name |
Dosage |
Price (wholesale) |
Approvals |
Manufacturer |
| Vivelle-Dot |
0.025 mg, 0.0375 mg, 0.05 mg |
$70–$100 |
FDA approved |
Novartis |
| Climara |
0.025 mg, 0.0375 mg, 0.05 mg |
$70–$90 |
FDA approved |
Bayer |
| Menostar |
0.5 mg/day |
$50–$70 |
FDA approved |
Mylan |
Given the aging population and increased HRT utilization, demand for transdermal estrogen remains stable but faces competition from branded and generic options.
Regulatory Environment
The FDA regulates transdermal hormone therapies. Patent exclusivities have expired for many formulations, increasing generic penetration. Pricing pressures are significant, and formulary inclusion influences sales volume.
Price Projections
Current Pricing Trends
Wholesale acquisition costs (WAC) for similar transdermal estrogen patches range from $50 to $100 per month, depending on the formulation strength and manufacturer.
| Year |
Projected WAC Price Range |
Rationale |
| 2023 |
$50–$100 |
Mature market, rising competition |
| 2024 |
$48–$95 |
Increased generic competition, pricing pressure |
| 2025 |
$45–$90 |
Longer-term decline expected, volume growth potential |
| 2026 |
$43–$85 |
Market saturation, continued price pressure |
| 2027 |
$40–$80 |
Stabilization at lower price points |
Factors Affecting Future Pricing
- Generic Market Entry: Increased generic availability will continue to suppress prices.
- Manufacturing Costs: Slight reductions expected due to process efficiencies.
- Reimbursement Policies: Medicaid and Medicare negotiations could push prices downward.
- Patent Status: Expired patents open the market for generics, affecting branded drug pricing.
Revenue Projections
Assuming annual sales volume of approximately 2 million units in the U.S., potential revenue can be estimated:
| Scenario |
Unit Price |
Total Revenue (USD) |
Notes |
| Optimistic (market share + volume growth) |
$80 |
$160 million |
Market expansion and volume growth |
| Conservative (market share plateau) |
$50 |
$100 million |
Price squeeze and competitive pressure |
Key Market Entry and Growth Opportunities
- Development of interchangeable generic versions can erode brand share.
- Expanding into emerging markets offers growth prospects, though at lower price points.
- Formulation innovations may allow premium pricing, especially if they improve bioavailability or adherence.
Risks and Challenges
- Price erosion from increased generics
- Stringent reimbursement and approval pathways
- Patent litigation delaying generic entry
- Competition from alternative therapies (e.g., oral estrogen pills, newer HRT formulations)
Final Considerations
The pricing trajectory for NDC 00904-7419 will align closely with industry trends toward commoditization and cost containment. Given existing market saturation and regulatory pressures, future prices are expected to decline gradually over the next five years.
Key Takeaways
- Estimated market size in the U.S. surpasses $1 billion annually.
- Price range for similar products is $50–$100 per unit.
- Price decline forecasted to reach $40–$80 in 5 years.
- Generic competition and reimbursement policies drive down prices.
- Revenue potential depends on market share, volume, and payer strategies.
FAQs
1. How does patent expiry influence the market for NDC 00904-7419?
Patent expiry allows generic manufacturers to produce lower-cost versions, increasing competition and applying downward pressure on prices.
2. Are there upcoming regulatory or market events that could impact prices?
The approval of biosimilars or new formulations, along with reimbursement policy adjustments, could influence pricing dynamics.
3. What are the main factors that determine pricing for transdermal estrogen products?
Manufacturing costs, competition, patent status, reimbursement policies, and formulary inclusion drive pricing.
4. How does the global market affect U.S. pricing?
Markets outside the U.S. often have lower prices, which can influence international availability and pricing strategies for the product.
5. What is the outlook for revenue growth in this market segment?
While overall demand remains stable, increased generics and pricing pressures limit growth opportunities. Market expansion into emerging regions offers upside.
References
- MarketWatch. (2022). Menopause market size and forecasts. [Online] Available at: https://www.marketwatch.com
- IQVIA. (2022). U.S. prescription drug trends report. [Online] Available at: https://www.iqvia.com
- FDA. (2022). Approved drug products database. [Online] Available at: https://www.accessdata.fda.gov
- CB Insights. (2023). BioPharma industry analysis. [Online] Available at: https://www.cbinsights.com
- Statista. (2022). Estimation of hormone therapy market revenue. [Online] Available at: https://www.statista.com
